Combined anti-tuberculosis drugs: Russian and international experience


Starshinova A.A.

1Saint Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of Russia, Saint Petersburg, Russia; 2Saint Petersburg State University, Saint Petersburg, Russia
To enhance the efficiency of treatment for tuberculosis is now one of the most pressing problems. The mid-20th century was marked by the discovery of medications to treat tuberculosis infection. Since the advent of chemotherapy regimens, there has been a need to design a «miraculous» tablet that could compete with a combination of anti-tuberculosis drugs in efficacy. The review analyzes the most important Russian and foreign publications and the results of meta-analyses, which show the high efficiency and economic feasibility of using combined drugs (CDs). Since 2011, scientists worldwide have argued that there is insufficient use of CDs that reduce the number of treatment withdrawals, increase patient adherence to treatment, reduce the number of adverse reactions and, consequently, improve the results of treatment, which prevents the development of multidrug-resistant Mycobacterium-caused tuberculosis.
Keywords: investigations, combined drugs, tuberculosis, therapy
Read entire article

Literature

  1. World Health Organization. Global tuberculosis report 2016. http://www.who.int/tb/en/
  2. Yablonskiy P.K, Vinogradova T.I, Levashov Yu.N, Pavlova M.V, Zilber E.K, Starshinova A.A, Sapozhnikova N.V, Chernockaeva I.V, Archakov L.I, Zabolotnykh N.V., Vitovskaya M.L. [Preclinical and clinical studies of the new anti-tuberculosis drug perchlorazon]. Ther. archive 2016 (3): 111–5. (In Russ.).
  3. Yablonskiу Р., Vizel A., Galkin V., Shulgina M. Tuberculosis in Russia its history and its status today. Am. J. Respir. Clin. Care Med. 2015; 191(4): 372–6.
  4. Ovchinnikova Yu.E., Dovgalyuk I.F., Starshinova A.A., Buchatskaya L.A. [Causes of chronic course of tuberculosis of intrathoracic lymph nodes in children, features of clinical manifestations and therapy]. Tuberkulez i bolezni legkih 2010; 87(1): 40–4. (In Russ.).
  5. Yablonskiy P.K., Vinogradova T.I., Pavlova M.V., Sapozhnikova N.V., Vasilieva S.N., Archakova L.I, Gushchin A.S. [New perspectives in the treatment of respiratory tuberculosis]. Medicinskiy alyans 2013; (2): 69–73. (In Russ.).
  6. Sabirov Sh.Yu., Rakhmanov Sh.A. [Surgical treatment of pulmonary tuberculosis with multiple drug-resistant pathogens]. Tuberkulez i bolezni legkih 2015; (6): 128–9. (In Russ.).
  7. Skornyakov S.N., Motus I.Ya., Kildyusheva E.I., Medvinsky I.D., Bazhenov A.V., Saveliev A.V. [Surgery of destructive drug-resistant pulmonary tuberculosis]. Tuberkulez i bolezni legkih 2015; (3): 15–21. (In Russ.).
  8. Starshinova A.A., Pavlova M.V., Yablonskiy P.K., Sapozhnikova N.V., Vinogradova T.I., Chernokhaeva I.V., Belyaeva E.N. [Evolution of phthisiology is the search for new methods and drugs effective in the treatment of tuberculosis.]. Prakticheskaya medicina 2014; (7): 127–32. (In Russ.).
  9. Chernokhaeva I.V., Pavlova M.V., Starshinova A.A., Belyaeva E.N., Sapozhnikova N.V., Gavrilov P.V., Zhuravlev V.Yu., Archakova L.I., Yablonskiy P.К. [Efficacy of lung tuberculosis therapy with multiple drug resistance of the causative agent with the use of thioureidoimiminopyridinium (perchlozone)]. Prakticheskaya medicina 2015; 1(3): 81–5. (In Russ.).
  10. Sterlikov S.A., Testov V.V., Vasileva I.A. [Results of treatment of patients with multiple and broad drug resistance of the pathogen, registered in 2012 in the Russian Federation and in the world]. Tuberkulez i bolezni legkih 2016; (1): 22–7. (In Russ.).
  11. [Tuberculosis in the Russian Federation 2012/2013/2014. Analytical review of statistical indicators used in the Russian Federation and in the world]. Мoscow, 2015. (In Russ.). http://www.fsvok.ru/news/analiticheskij-obzor-statisticheskih-pokazatelej-ispolzuemyh-v-rossijskoj-federatsii-i-v-mire-tuberkulez-v-rossijskoj-federatsii-201220132014-gg-
  12. Chernokhaeva I.V. [Monitoring of unwanted reactions against the background of therapy of respiratory tuberculosis with multiple drug resistance of the pathogen with the use of thioureidoiminomethyl pyridinium (perchlorazone)]. Medicinskiy alyans 2014; (2): 59–65. (In Russ.).
  13. Marfina G.Yu., Vladimirov K.B., Kudryashov G.G., Istomina E.E., Avetisyan A.O. [The case of effective complex treatment of bilateral fibrous-cavernous pulmonary tuberculosis with broad drug resistance of mycobacteria in a patient with severe tolerance of antituberculous therapy]. Tuberkulez i bolezni legkih 2017; (3): 62–8. (In Russ.).
  14. Mokhireva L.V. [The effectiveness of combined antituberculous drugs in patients with newly diagnosed pulmonary tuberculosis]. Dr, Med. Sci. Мoscow, 2015. (In Russ.). https://search.rsl.ru/ru/record/01005531294
  15. Borisov S.E., Ivanushkina T.N., Litvinova N.V., Ivanova D.A., Garmash Yu.Yu., Slogotskaya A.V., Fillipova A.V., Matveeva M.V. [Ways to increase the effectiveness of etiotropic treatment of tuberculosis patients. Scientific works. To the 70th anniversary of V.I. Litvinov]. Мoscow, 2011. 248 р. (In Russ.).
  16. Sokolova G.B., Lazareva Ya.V. [IZOPASK is a new combined antituberculous drug]. Tuberkulez i bolezni legkih 2010; (4): 61–4. (In Russ.).
  17. Su W.J., Perng R.P. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. Int. J. Tuberc. Lung Dis. 2002; 6(11): 1029–32.
  18. Bangalore S., Kamalakkannan G., Parkar S., Messerli F.H. Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis. Am. J. Med.2007; 120(8): 713–9.
  19. Рanchagnula R., Parmar J., Kaur K., Singh I., Bade S.R, Ashokraj Y. Statistical evaluation of physiological variability of rifampicin in fixed dose combinations. Int. J. Pharm. 2006; 313(1–2); 5–13.
  20. Bartacek A., Schьtt D., Panosch B., Borek M., on behalf of the Rimstar® 4-FDC Study Group. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. J. Tuberc. Lung Dis. 2009; 13(6): 760–6.
  21. Evidence for promoting fixed-dose combination drugs in tuberculosis treatment and control: a review. Int. J. Tuberc. Lung Dis. 2011; 15 (4): 433–9.
  22. Lienhardt C., Cook S.V., Burgos M., Yorke-Edwards V., Rigouts L, Anyo G., Kim S.J., Jindani A., Enarson D.A., Nunn A.J. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. JAMA 2011; 305(14); 1415–23.
  23. Wu J.T., Chiu C.T., Wei Y.F., Lai Y.F. Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment. Clinics 2015; 70(6): 429–34.
  24. Aseffa А., Chukwu J.N., Vahedi M., Aguwa E.N., Bedru A., Mebrahtu T. et al. Efficacy and Safety of ‘Fixed Dose’ versus ‘Loose’ Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB Burden African Countries: A Randomized Controlled Trial. PLoS One 2016; 11(6): e0157434. DOI: 10.1371/journal.pone.0157434.
  25. Gallardo C.R., Rigau Comas D., Valderrama Rodríguez A., Roqué i Figuls M., Parker L.A., Caylà J., Bonfill Cosp X.. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. Cochrane Database of Systematic Reviews 2016: 5. http://www. cochranelibrary.com
  26. Zuev A.P., Mokhireva L.P., Yurchenko L.I., Morozova T.I. [Phtisoetam B6 and Ftyzopyram B6 in the treatment of newly diagnosed tuberculosis patients with the release of mycobacteria]. Tuberkulez i bolezni legkih 2012; (5): 44–53. (In Russ.).
  27. Lomova L.A. [Evaluation of the effectiveness and safety of COMBITUB-NEO® combined preparation in the treatment of patients with advanced forms of pulmonary tuberculosis]. Razrabotka i registraciya lekarstvennykh sredstv 2013; 5(5): 120–2. (In Russ.).
  28. Morozova T.I., Doktorova N.P., Barinboyn O.N., Parolina L.E [Clinical study of the use of combined chemo-preparations in the complex treatment of tuberculosis patients]. Sovremennye problemy nauki i obrazovaniya 2013; (2): 1–12. (In Russ.).
  29. Kildyusheva E.I., Skornyakov S.N., Medvinskiy I.D., Kravchenko M.A., Guschin A.S. [Combined drug IZOPASK in the complex treatment of patients with pulmonary tuberculosis with multiple drug resistance of the pathogen]. Ftiziatriya i pulmonologiya 2014; 1(8): 29–34. (In Russ.).
  30. Ovchinnikova Yu.E., Starshinova A.A., Dovgalyuk I.F. [Efficacy of using isoniazid 150 mg + pyrazinamide 375 mg + rifampicin 150 mg in the treatment of tuberculosis of respiratory organs in children]. Tuberkulez i bolezni legkih 2017; (7): 48–53. (In Russ.).
  31. Kavtarashvili S.M., Kazakov A.V., Milyankova I.E., Madasova V.G. [Adherence to the treatment of tuberculosis in the use of dispersible tablets in children and adolescents]. Medicinskiy alyans 2015; (3): 76–9. (In Russ.).
  32. Filippov A.V., Mokhireva L.V., Ivanushkina T.N., Ivanova D.A., Litvinova N.V., Borisov S.E. [A new combined antituberculous drug levofloripin in the treatment of newly diagnosed tuberculosis with the disintegration of lung tissue and bacterial excretion]. Tuberkulez i bolezni legkih 2012; 89(9): 38–45. (In Russ.).
  33. Kulikov A.Yu., Mokhireva L.V., Sorokovnikov I.V., Mokhirev A.V [Pharmacological study of the use of a combined antituberculous drug levofloripin in the complex treatment of tuberculosis patients]. Tuberkulez i bolezni legkih 2012; (11): 62–9. (In Russ.).


About the Autors

For correspondence:
Anna A. Starshinova, MD, Leading Researcher, Saint Petersburg Research Institute of Phthisiopulmonology, Ministry of Health of Russia; Leading Researcher, Saint Petersburg State University
Address: 2–4, Ligovsky Prospekt, Saint Petersburg191036, Russia
Fax: 8(812) 579-25-73
Е-mail: starshinova_777@mail.ru


Similar Articles

Back to Content

Бионика Медиа